Skip to content
Austin Top 50
Author:
iDEL Therapeutics GmbH
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
November 9, 2026